Home
About
- Overview
- Team
- Investors
Science
Pipeline
Partners
News & Events
Contact
Menu Menu

GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup

9 November 2022

Endpoints

https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg 819 1238 Webadm https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png Webadm2022-11-09 08:00:562026-08-14 16:12:46GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup

© NRG Therapeutics

Terms & Conditions
Privacy Policy

NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics...

NRG closes £16M series A to fund fight against neurodegenerative diseases